These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30443191)

  • 1. PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis.
    Wang Y; Hao F; Nan Y; Qu L; Na W; Jia C; Chen X
    Int J Biol Sci; 2018; 14(13):1883-1891. PubMed ID: 30443191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.
    Wang X; Zhang F; Wu XR
    Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor Effect of Shikonin, a PKM2 Inhibitor, in Cholangiocarcinoma Cell Lines.
    Thonsri U; Seubwai W; Waraasawapati S; Wongkham S; Boonmars T; Cha'on U; Wongkham C
    Anticancer Res; 2020 Sep; 40(9):5115-5124. PubMed ID: 32878800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.
    Li W; Liu J; Zhao Y
    Mol Carcinog; 2014 May; 53(5):403-12. PubMed ID: 23255458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line.
    Yang W; Liu J; Hou L; Chen Q; Liu Y
    Life Sci; 2021 Jan; 265():118796. PubMed ID: 33220292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.
    Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G
    Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
    Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
    J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor M2-PK: A novel urine marker of bladder cancer.
    Liu W; Woolbright BL; Pirani K; Didde R; Abbott E; Kaushik G; Martin P; Hamilton-Reeves J; Taylor JA; Holzbeierlein JM; Anant S; Lee EK
    PLoS One; 2019; 14(6):e0218737. PubMed ID: 31246990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shikonin Suppresses Skin Carcinogenesis via Inhibiting Cell Proliferation.
    Li W; Zhang C; Ren A; Li T; Jin R; Li G; Gu X; Shi R; Zhao Y
    PLoS One; 2015; 10(5):e0126459. PubMed ID: 25961580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer.
    Liu X; Liu L; Wang X; Jin Y; Wang S; Xie Q; Jin Y; Zhang M; Liu Y; Li J; Wang Z; Fu X; Jin CY
    Phytomedicine; 2023 Sep; 118():154943. PubMed ID: 37421765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
    Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
    Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis.
    Tao T; Su Q; Xu S; Deng J; Zhou S; Zhuang Y; Huang Y; He C; He S; Peng M; Hocher B; Yang X
    J Cell Physiol; 2019 Mar; 234(3):3088-3104. PubMed ID: 30221356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis.
    Fu Z; Deng B; Liao Y; Shan L; Yin F; Wang Z; Zeng H; Zuo D; Hua Y; Cai Z
    BMC Cancer; 2013 Dec; 13():580. PubMed ID: 24314238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway.
    Shahsavari Z; Karami-Tehrani F; Salami S; Ghasemzadeh M
    Tumour Biol; 2016 Apr; 37(4):4479-91. PubMed ID: 26496737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
    Tang JC; Ren YG; Zhao J; Long F; Chen JY; Jiang Z
    Life Sci; 2018 Jul; 204():71-77. PubMed ID: 29738778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line (T24).
    Yeh CC; Kuo HM; Li TM; Lin JP; Yu FS; Lu HF; Chung JG; Yang JS
    In Vivo; 2007; 21(6):1011-9. PubMed ID: 18210748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells.
    Cho HJ; Kim JK; Kim KD; Yoon HK; Cho MY; Park YP; Jeon JH; Lee ES; Byun SS; Lim HM; Song EY; Lim JS; Yoon DY; Lee HG; Choe YK
    Cancer Lett; 2006 Jun; 237(1):56-66. PubMed ID: 16009487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.
    Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X
    Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shikonin kills glioma cells through necroptosis mediated by RIP-1.
    Huang C; Luo Y; Zhao J; Yang F; Zhao H; Fan W; Ge P
    PLoS One; 2013; 8(6):e66326. PubMed ID: 23840441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
    Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.